Anti-IL-4Rα antibody dupilumab which blocks both IL-4 and IL-13 signaling and anti-IL-13 antibody including tralokinumab and lebrikizumab show clinical efficacy in AD (38–41). Here, IL13 is linked to Alzheimer disease.